Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MAb Therapy Nucala's Approval Splits EU, US Regulatory Opinion On Age Range

This article was originally published in SRA

Executive Summary

European and US regulators have taken differing views on whether GlaxoSmithKline's new MAb therapy for severe eosinophilic asthma, Nucala (mepolizumab), should be indicated for use in adolescents, indicating that even after years of collaboration, they go their own way when making final decisions.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS118476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel